Shanghai Pharmaceutical (manufacturing segment)

Shanghai Pharmaceuticals reported revenue of CNY 275.3B ($38.4B) in 2024, representing a 5.7% YoY increase. As China's second-largest medical distributor, the company has significantly increased its R&D investment to 10.1% of manufacturing revenue in 2024, up from 4.2% in 2013. Recent strategic moves include the acquisition of HUTCHMED's 45% equity stake in Shanghai Hutchison Pharmaceuticals for $608M, strengthening its portfolio and market position.